SCHEMBL5215401

SCHEMBL5215401

Cc1ccc(Br)cc1-n1cc(-c2cnc3ccccc3n2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.51
JAK2 O60674 2/20 0.45
RAB9A P51151 7/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KDR P35968 3/20 0.41
PDGFRB P09619 1/20 0.41
FLT3 P36888 1/20 0.41
FGFR3 P22607 2/20 0.40
MAPT P10636 5/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.40
ALOX12 P18054 1/20 0.40
MAPK10 P53779 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
BCHE P06276 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217439 0.88 NPC1 (0.53) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5217660 0.85 NPC1 (0.51) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5220308 0.84 NPC1 (0.49) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5219705 0.81 JAK2 (0.47) NPC1JAK2KDRFLT3KDM4E
SCHEMBL5219172 0.81 NPC1 (0.50) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL8357642 0.81 NPC1 (0.50) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5220712 0.80 NPC1 (0.44) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL5217700 0.79 NPC1 (0.45) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5216003 0.79 NPC1 (0.62) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5215183 0.79 NPC1 (0.48) NPC1JAK2RAB9ASMN1; SMN2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885JAK2 1569/4885RAB9A 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.